April 20, 2021
15:00–16:30 CEST / 9:00–10:30 EDT
Precise genetic editing technologies allow researchers to excise, insert and alter targeted regions in genomes, opening new possibilities from gene therapies to plant breeding. Coupled to that potential is an effort to make edits tractable and certain. Join Eric Paul Bennett and Keyi Geng in this two-part webinar discussing unanticipated alterations happening after gene editing and ways to detect and characterize expected and unexpected outcomes.
Eric Paul Bennett, MSc, Dr. Med., COBO Technologies(15:00 CEST)
Brief survey of the pros and cons of current gene editing InDel detection methodologies
Are InDels the only outcomes to be expected after gene editing?
Choice of “fit for purpose” InDel detection methodology
Eric has decades of experience establishing precision engineered isogenic cells lacking individual genes involved in glycosylation. He has spearheaded methods and workflows to address unmet needs in the field, improving the targeting and indel detection efficacy of precise genome editing applications. He is a co-founder of COBO Technologies.
Keyi Geng, PhD Student, Karolinska Institute(15:30 CEST)
Two cancer model cell lines were modfied with CRISPR-Cas9 to excise a region of interest, but show evidence that the targeted sequence is still present and functional in the modified cells
Target-specific PCR and Sanger sequencing, however, appeared to confirm the removal of the region of interest from the intended edit site
Keyi received her Master's Degree from Shanghai Jiao Tong University (China) working on cerebral ischemia and cellular senescence. She is now a PhD student in Claudia Kutter's lab at the Karolinska Institute (Stockholm, Sweden), focusing on deciphering tRNA gene functionality using CRISPR/Cas9 and various sequencing technologies.
ContactBregnerødvej 963460 BirkerødDenmark
email@example.comPhone: (+45) 82 30 45 00
CVR 32 30 93 21
Connect with us
Copyright © 2022 Samplix® ApS. All rights reserved. For Research Use Only. Not for use in diagnostic procedures.
Web design: www.reklamehuset.dk
Samplix ApS is a biotechnology company. Our website includes information on our proprietary products and their applications in gene and cell screening, as well as our services offering. It's possible to create a customer account to use bioinformatics tools used for our workflows.